Taking a multidisciplinary approach
prefers to approach problems from a multidisciplinary viewpoint. She studied physics as an undergraduate at the University of Chicago and then expanded to biophysics — combining biology, chemistry and physics — for her Ph.D. at the University of California, San Francisco.

“Even when I did my Ph.D., … I worked at the interface between doing experimental crystallography and computational molecular dynamics,” she said, “and that continues to this day when I apply biophysics, structural biology and chemistry to elucidating the molecular mechanisms of drug resistance in quickly evolving diseases
For her multidisciplinary work on drug resistance, Schiffer will receive the 91影库 and Molecular Biology 2020/2021 William C. Rose Award recognizing contributions to biochemical and molecular biological research and commitment to the training of younger scientists.
Schiffer started the Institute for Drug Resistance in the University of Massachusetts Medical School, which she currently heads. Her lab is known for a culture that enables researchers from diverse backgrounds to pursue their work amicably within the group.
“My lab has gained the reputation for being a friendly, supportive place to learn and do science,” Schiffer said.
She believes being respectful to fellow researchers is the key to a successful lab where science can be pursued without stresses that often selectively affect international students and those from underrepresented minority backgrounds.
Schiffer finds that some students suffer from imposter syndrome — believing they are not as good as their peers — despite what their professors or peers actually think. Exposure to broader scientific platforms, such as attending conferences, helps these students realize their potential, she said.
“I try to encourage my students so that they are able to see how their project fits into the bigger picture.”
Beating drug resistance
Much of Celia Schiffer’s work is on elucidating how mutations in drug targets affect resistance to the drug. Schiffer is interested in the specificity of molecular recognition.
“Drug resistance occurs as a result of evolution,” she said, “when drug pressure changes the balance of molecular recognition events, selectively weakening inhibitor binding by mutation while maintaining the biological function of the therapeutic target.” These changes involve alteration of both the structure and the dynamics of the target.
In her award lecture at the 2020 91影库annual meeting, Schiffer will talk about strategies to avoid drug resistance in the drug-design process.
One such strategy arose from her team’s recognition that many resistance mutations occur where the inhibitor protrudes beyond the volume necessary for substrate recognition.
By targeting an inhibitor to the substrate envelope, the probability of resistance can be decreased, as a mutation impacting the inhibitor binding will compromise substrate turnover.
“We discovered and validated this strategy through inhibitor design and testing in several systems,” Schiffer said. These systems include viral proteases in HIV and hepatitis C. The concept is broadly applicable to other quickly evolving diseases such as cancer.
Enjoy reading 91影库Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from 91影库Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in People
People highlights or most popular articles

From dust to discovery
From makeshift classrooms in Uganda to postdoctoral research in Chicago, MOSAIC scholar Elizabeth Kaweesa builds a legacy in women鈥檚 health.

Fliesler wins scientific and ethical awards
He is being honored by the University at Buffalo and the American Oil Chemists' Society for his scientific achievements and ethical integrity.

Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.

91影库members recognized as Allen investigators
Ileana Cristea, Sarah Cohen, Itay Budin and Christopher Obara are among 14 researchers selected as Allen Distinguished Investigators by the Paul G. Allen Family Foundation.

AI can be an asset, 91影库educators say
Pedagogy experts share how they use artificial intelligence to save time, increase accessibility and prepare students for a changing world.